This is important since the inhibition of one HIFα subunit, e.g., HIF-1α, induces the over-expression of HIF-2α, and thus, inhibitors targeting simultaneously HIF-1 and HIF-2 may be more effective in the therapy of some cancer types [58]. Here, EPAS1 is linked to cancer.